VELOCITY-HNSCC Substudy-01: A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status

Status

Terminated

Disease

head and neck squamous cell carcinoma (HNSCC)

Treament Agent

Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin

Study Phase

Phase II

Resources and Links

https://clinicaltrials.gov/study/NCT06727565

Physician Name(s)

Dr Hilawati Yusof

Description

This platform study will begin with a substudy targeting first-line (1L) recurrent or metastatic (r/m) HNSCC regardless of programmed cell death ligand 1 (PD-L1) expression status (Substudy-01), and new substudies may be added in the future targeting different study populations of HNSCC. All substudies evaluating additional drugs will be added in a staggered manner when relevant nonclinical and/or clinical data become available. Additional drugs may also be added to Substudy-01 in the future. (GS-US-699-7184-01) Substudy-01 will evaluate the efficacy and safety of novel combination of treatment regimens, domvanalimab (DOM) and zimberelimab (ZIM) combined with chemotherapy vs ZIM combined with chemotherapy. The primary objective is to assess the efficacy of DOM and ZIM in combination with chemotherapy versus ZIM in combination with chemotherapy.

Cancer Type

Head and Neck Cancer

I would like to be a part of tomorrow's breakthrough

Clinical trials are part of research studies involving patient volunteers that are conducted to find safe and effective treatments for a variety of health conditions. They are critical to the advancement of medicine and improving patient health. Participating in clinical trials offers patients the opportunity to try new and effective treatments that could potentially improve their condition while taking part in vital research that can benefit many future patients.

In Pantai Hospital Kuala Lumpur, clinical trials are carried out under our Clinical Research team.

If you would like to participate in any of our clinical trials or would like to know, please provide your information below and we will be in touch with you: